2020 (3 POSTS)
Chappell GA, Thompson CM , Wolf JC, Cullen JM, Klaunig JE, Haws LC . 2020. Assessment of the mode of action underlying the effects of GenX in mouse liver and implications for assessing human health risks. Toxicol Pathol 48(3):494–508; doi: 10.1177/0192623320905803 . PMID: 32138627.
View Abstract
Publication: Manuscripts
Haws L (session co-chair). Introduction to “Use of New Approach Methods in Risk Characterization of PFAS: Challenges and Opportunities.” 44th Annual Winter Meeting, the Toxicology Forum, Tysons, VA, January 2020.
Publication: Abstracts and Presentations
Thompson CM , Ring C, Pham L, Chappell GA, Haws LC . Assessment of the relevance of toxicological findings in the development of an oral reference dose for GenX. Poster for Society of Toxicology 59th Annual Meeting, Virtual, 2020.
View Abstract
Publication: Abstracts and Presentations
2019 (6 POSTS)
Thompson C , Chappell G, Cullen J, Wolf JC, Haws L. Development of an oral reference dose for GenX using the latest toxicological and risk assessment methodologies: Environmental risk assessment of per- and polyfluoroalkyl substances (PFAS). SETAC North America Focused Topic Meeting, Durham, NC, August 2019.
Publication: Abstracts and Presentations
Chappell GA, Thompson CM , Wolf J, Cullen J, Haws LC. Transcriptomic responses in livers of GenX-treated mice demonstrate up-regulation of PPAR signaling and related pathways. Environmental Mutagenesis and Genomics Society, Washington, DC, September 2019.
Publication: Abstracts and Presentations
Thompson CM . The useful chemistry of perfluorinated compounds: Managing safety. The sticky subject of non-stick: Regulatory science challenges of per- and poly-fluorinated compounds (PFAS). Texas A&M University Interdisciplinary Faculty of Toxicology Training Program, 2019 Annual Regulatory Science Symposium, August 2019.
Publication: Abstracts and Presentations
Thompson CM , Fitch SE , Ring C, Rish W , Cullen JM, Haws LC . 2019. Development of an oral reference dose for the perfluorinated compound GenX. J Appl Toxicol 39(9):1267–1282; doi: 10.1002/jat.3812 .
View Abstract
Publication: Manuscripts
Ring CL, Rish WR, Brorby GL . Prioritization of eight PFAS by population exposure and reference-dose uncertainty. Poster session at SETAC North America Focused Topic Meeting “Environmental Risk Assessment of PFAS”, Durham, NC, August 2019.
Publication: Abstracts and Presentations
Borghoff SJ , Fitch S , Huggett, Wikoff D . A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine disrupting properties of perfluorohexanoic acid (PFHxA). 2019. Poster at Society of Toxicology Annual Meeting, Baltimore, MD, March 2019.
View Abstract
Publication: Abstracts and Presentations
2018 (2 POSTS)
Borghoff SJ, Fitch S , Rager JE, Huggett D. 2018. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine activity of perfluorohexanoic acid. Regul Toxicol Pharmacol 99(Nov):168–181; doi: 10.1016/j.yrtph.2018.09.001 .
View Abstract
Publication: Manuscripts
Kempisty DM, Xing Y, Racz L (eds). 2018. Perfluoroalkyl Substances in the Environment: Theory, Practice and Innovation. Taylor and Francis CRC Press: Boca Raton, FL.
View Abstract
Publication: Book (editor)
2007 (1 POST)
Paustenbach DJ, Panko JM , Scott PK, Unice KM. 2007. A methodology for estimating human exposure to perfluorooctanoic acid (PFOA): A retrospective exposure assessment of a community (1951-2003). J Toxicol Environ Health A 70(1):28–57; doi: 10.1080/15287390600748815 .
View Abstract
Publication: Manuscripts
2006 (2 POSTS)
Paustenbach DJ, Panko JM , Scott PK, Unice KM. Retrospective modeling of potential residential exposure to perfluorooctanoic acid (PFOA) releases from a manufacturing facility. Society of Toxicology 45th Annual Meeting, San Diego, CA, March 2006.
Publication: Abstracts and Presentations
Lau C, Thibodeaux JR, Hanson RG, Narotsky MG, Rogers JM , Lindstrom AB, Strynar MJ. 2006. Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. Toxicol Sci 90(2):510–518; doi: 10.1093/toxsci/kfj105 .
View Abstract
Publication: Manuscripts
2005 (2 POSTS)
Grasty RC , Bjork JA, Wallace KB, Lau CS, Rogers JM . 2005. Effects of prenatal perfluorooctane sulfonate (PFOS) exposure on lung maturation in the perinatal rat. Birth Defects Res B 74(5):405–416; doi: 10.1002/bdrb.20059 .
View Abstract
Publication: Manuscripts
Grasty RC , Roberts N, Klinefelter G, Bjork JA, Wallace KB, Lau CS, Rogers JM . 2005. Effects of prenatal perfluorooctanesulfonate (PFOS) exposure on lung maturation in the perinatal rat. Birth Defects Res A 73:314.
Publication: Abstracts and Presentations
2004 (3 POSTS)
Lau C, JL Butenhoff, JM Rogers. 2004. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol Appl Pharmacol 198(2):231-241; doi: 10.1016/j.taap.2003.11.031 .
View Abstract
Publication: Manuscripts
Grasty RC , Roberts N, Grey BE, Lau C, Rogers JM . Effects of prenatal exposure to perfluorooctane sulfonate on the developing lung in the rat. Society for Toxicology 43rd Annual Meeting, Baltimore, MD, March 2004.
Publication: Abstracts and Presentations
Grasty RC , Roberts N, Grey BE, Lau C, Rogers JM. 2004. Perfluorooctane sulfonate (PFOS) alters lung development in the neonatal rat. Birth Defects Res A 70(5):42.
Publication: Abstracts and Presentations
2003 (4 POSTS)
Grasty RC , Grey BE, Lau CS, Rogers JM. 2003. Window of susceptibility to perfluorooctane sulfonate (PFOS)-induced neonatal mortality in the rat. Birth Defects Research B 68(3):5.